- Home
- LSTA
as 11-15-2024 4:00pm EST
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | BASKING RIDGE |
| Market Cap: | 24.2M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 15.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.05 - $3.83 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Lisata Therapeutics Inc. News
LSTA Breaking Stock News: Dive into LSTA Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
5 days ago
Q3 2024 Lisata Therapeutics Inc Earnings Call
GuruFocus.com
5 days ago
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...
GlobeNewswire
5 days ago
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12 days ago
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
GlobeNewswire
12 days ago
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
Zacks
16 days ago
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
GlobeNewswire
18 days ago
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
GlobeNewswire
21 days ago
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Compare LSTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LSTA Lisata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.